Autopsy report · NCT00123877
Study of GPX-100 in the Treatment of Metastatic Breast Cancer
Cause of deathNo reason given
Life of this trial
- Registered 4 months after it had already started.
- Ran for about 8 months before it stopped.
- 40 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Gem Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Breast Cancer; Metastasis
- Interventions
- GPX-100 (13-deoxydoxorubicin)
- Participants
- 40
- Sites
- 3
- Countries
- Bulgaria, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.